Alzinova Seeks US Ethical Approval for Phase 2a Alzheimer's Vaccine Study

MT Newswires · 1d ago
05:59 AM EST, 11/03/2026 (MT Newswires) -- Alzinova (ALZ.ST) applied to the US Institutional Review Board Advarra for ethical review and approval of its planned phase 2a Advance study of vaccine candidate ALZ-101 in patients with early Alzheimer's disease. The Swedish biopharmaceutical company said Tuesday that the submission covers seven selected US clinical trial sites, with first patient enrollment expected at the end of 2026 or the beginning of 2027.